Last reviewed · How we verify
NRP104
NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD).
NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD). Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | NRP104 |
|---|---|
| Also known as | lisdexamfetamine dimesylate |
| Sponsor | New River Pharmaceuticals |
| Drug class | Sympathomimetic amine; ADHD stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
NRP104 is a long-acting prodrug formulation of d-amphetamine designed to provide extended therapeutic coverage. The drug is metabolized in the body to release d-amphetamine, which acts as a sympathomimetic amine that increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system, thereby improving attention and reducing hyperactivity and impulsivity in ADHD patients.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Decreased appetite
- Insomnia
- Headache
- Abdominal pain
- Increased heart rate
- Elevated blood pressure
Key clinical trials
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder (PHASE2)
- Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users (PHASE2)
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (PHASE2, PHASE3)
- Vyvanse in Children Aged 6 to 12 Years (EARLY_PHASE1)
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (PHASE3)
- Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder (PHASE2)
- Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRP104 CI brief — competitive landscape report
- NRP104 updates RSS · CI watch RSS
- New River Pharmaceuticals portfolio CI